Hypotrichosis clinical trials
The registry lists 24 studies for Hypotrichosis across more than 10 countries. 2 are recruiting or about to start. 20 of them are mainly about Hypotrichosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06. Counting its 3 narrower conditions too, such as Alopecia: 716 studies, 176 open.
Get an email when these change. Save the Hypotrichosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Allergan (11) · Quantum Aesthetics Cosmetics (2) · Mae Fah Luang University Hospital (2) · Aneira Pharma, Inc. (1) · Duke University (1) · Northwestern University (1) · Skin Care and Laser Physicians of Beverly Hills (1) · Almirall, S.A. (1)
What is being tested here
Drugs under test in Hypotrichosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Baricitinib | 1 | 1 | 1 |
| Bimatoprost | 0 | 2 | 6 |
| Bimatoprost Ophthalmic Solution | 0 | 0 | 1 |
| Latanoprost | 0 | 0 | 1 |
| Minoxidil | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- May 2027Platelet-rich Plasma for Eyebrows · Northwestern University
- Jun 2027A Study of LAD603 in Adults With Alopecia Areata · Almirall, S.A.
Who these studies take
Of the 2 Hypotrichosis studies recruiting now, 0 (0%) set no upper age limit and 2 (100%) stop at 75 or younger. 1 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (50%) | 1 (50%) |
| 18 | 1 (50%) | 1 (50%) |
| 30 | 1 (50%) | 1 (50%) |
| 40 | 1 (50%) | 1 (50%) |
| 50 | 1 (50%) | 1 (50%) |
| 65 | 1 (50%) | 1 (50%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 24 studies, recruiting or not: 46% stop at 75 or younger and 38% at 65; 4% take children; 17% are for women only and 0% for men only; 25% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 24 of 24. search them.
- A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataRecruitingNCT05723198Phase 312 countries
- A Study of LAD603 in Adults With Alopecia AreataRecruitingNCT07311564Phase 21 country
- Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash HypotrichosisCompletedNCT07776028Phase 41 country
- Evaluation of the Efficacy and Safety of Dallixa® Eyebrow Serum (Produced by Quantum Aesthetics Cosmetics, Turkey) in Subjects With Eyebrow HypotrichosisCompletedNCT07775989Not applicable1 country
- Platelet-rich Plasma for EyebrowsActive, not recruitingNCT04018859Phase 21 country
- A Study of KL130008 in Adults With Severe Alopecia AreataTerminatedNCT05496426Phase 21 country
- Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical FormulationStatus unknownNCT05790941Early Phase 11 country
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash HypotrichosisCompletedNCT01391273Phase 31 country
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash HypotrichosisCompletedNCT01391286Phase 31 country
- Bimatoprost for the Treatment of Eyebrow HypotrichosisCompletedNCT01765764Phase 32 countries
- An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the EyelashesCompletedNCT016234791 country
- Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean SubjectsCompletedNCT01229423Phase 41 country
- Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in JapanCompletedNCT025057761 country
- Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic AlopeciaStatus unknownNCT02999737Phase 41 country
- Bimatoprost in the Treatment of Eyelash HypotrichosisCompletedNCT01698554Phase 34 countries
- Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning EyebrowsCompletedNCT01891487Phase 41 country
- Study of Bimatoprost Gel on Eyelash GrowthCompletedNCT01200251Phase 31 country
- Minoxidil 1% for Eyebrow EnhancementCompletedNCT01924000Phase 41 country
- Minoxidil 2% for Eyebrow EnhancementCompletedNCT01672307Phase 41 country
- Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash ProminenceCompletedNCT01448525Phase 41 country
- Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid MarginCompletedNCT00907426Phase 32 countries
- Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus PlaceboCompletedNCT01387906Phase 41 country
- Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash HypotrichosisCompletedNCT00958035Phase 41 country
- Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash ProminenceCompletedNCT01064882Phase 21 country